Key Developments: Aspen Technology Inc (AZPN.O)
6 Dec 2013
Latest Key Developments (Source: Significant Developments)
Aspen Technology, Inc. Raises FY 2012 Revenue And EBIT Guidance; Reaffirms FY 2012 EPS Guidance; Issues Q3 2012 Guidance Below Analysts' Estimates-Conference Call
Aspen Technology, Inc. announced that it is now expecting fiscal 2012 revenue of $235 million to $240 million, which is up from its original guidance of $225 million to $235 million. GAAP operating loss is expected to be in the range of $23 million to $33 million, which is an improvement from its prior guidance of $30 million to $40 million. The Company continues to assume a GAAP net loss of $20 million to $30 million, or a loss of $0.21 to $0.32 per share. From a non-GAAP perspective, the Company now expects a non-GAAP operating loss (EBIT) in the range of $13 million to $23 million, an improvement from its prior guidance of non-GAAP operating loss of $20 million to $30 million. The Company continues to expect a non-GAAP loss per share (EPS) of $0.09 to $0.19, which is consistent with its prior guidance. For the third quarter of 2012, the Company expects revenue of approximately $57 million to $60 million, GAAP operating loss in the range of $8 million to $10 million, non-GAAP operating loss of approximately $5.5 million to $7.5 million. According to I/BE/S Estimates, analysts on an average were expecting the Company to report revenue of $236 million, EBIT of $(26) million and EPS of $(0.16) for fiscal 2012; and revenue of $62 million and EBIT of $(4) million for the third quarter of 2012. Full Article
LONDON - GlaxoSmithKline said on Tuesday it planned to reduce its investment in South African drugmaker Aspen Pharmacare by one third, although it would retain a board seat and a significant shareholding.